ArticleJournal of imaging2025
Prediction of PD-L1 and CD68 in Clear Cell Renal Cell Carcinoma with Green Learning.
Article in Journal of imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CT-Based Radiomics for Prediction of Molecular Markers in Clear Cell Renal Cell Carcinoma: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Artificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects.The Canadian journal of urology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cancer. Extensive efforts have been made to utilize radiomics from computed tomography (CT) imaging to predict tumor immune microenvironment (TIME) measurements. This study proposes a Green Learning (GL) framework for approximating tissue-based biomarkers from CT scans, focusing on the PD-L1 expression and CD68 tumor-associated macrophages (TAMs) in ccRCC. Our approach includes radiomic feature extraction, redundancy removal, and supervised feature selection through a discriminant feature test (DFT), a relevant feature test (RFT), and least-squares normal transform (LNT) for robust feature generation. For the PD-L1 expression in 52 ccRCC patients, treated as a regression problem, our GL model achieved a 5-fold cross-validated mean squared error (MSE) of 0.0041 and a Mean Absolute Error (MAE) of 0.0346. For the TAM population (CD68+/PanCK+), analyzed in 78 ccRCC patients as a binary classification task (at a 0.4 threshold), the model reached a 10-fold cross-validated Area Under the Receiver Operating Characteristic (AUROC) of 0.85 (95% CI [0.76, 0.93]) using 10 LNT-derived features, improving upon the previous benchmark of 0.81. This study demonstrates the potential of GL in radiomic analyses, offering a scalable, efficient, and interpretable framework for the non-invasive approximation of key biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.